Twist Bioscience
Twist Bioscience raises $200M Convertible Note at $4B valuation
Quick Facts
Twist Bioscience: Convertible Note Funding Round
Twist Bioscience has successfully raised $200M in Convertible Note funding, reaching a valuation of $4B.
Company Overview
Synthetic DNA manufacturing
Funding Details
The Convertible Note round was led by Temasek Holdings, with participation from Fidelity, Paladin Capital Group, Casdin Capital.
Company Information
- Headquarters: 681 Gateway Boulevard, South San Francisco, CA 94080
- Founded: 2013
- Employees: 600+
- Category: Biotech
Investment
Twist Bioscience plans to use the funds to accelerate product development, expand its team, and scale operations globally.
About the Investors
- Temasek Holdings: Verified investor in Convertible Note
- Fidelity: Verified investor in Convertible Note
- Paladin Capital Group: Verified investor in Convertible Note
- Casdin Capital: Verified investor in Convertible Note
Key Investors
About the Author
Related Company Reports
Torl Biotherapeutics raises $96M Series C at $500M valuation
Torl Biotherapeutics raises $96M in Series C at $500M valuation. Antibody-based immunotherapies for cancer patients...
Nilo Therapeutics raises $101M Series A at $450M valuation
Nilo Therapeutics raises $101M in Series A at $450M valuation. Developing therapies based on neuro-immunology research...
Arthrosi Therapeutics raises $153M Series E at $800M valuation
Arthrosi Therapeutics raises $153M in Series E at $800M valuation. Developing next-generation gout treatment drug for chronic conditions...